<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417530</url>
  </required_header>
  <id_info>
    <org_study_id>AU-011-202</org_study_id>
    <nct_id>NCT04417530</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma</brief_title>
  <official_title>A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aura Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aura Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection
      to treat primary indeterminate lesions and small choroidal melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase
      (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase
      Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate
      Lesions and Small Choroidal Melanoma.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential for dose escalation phase and parallel for randomized dose expansion phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Initial dose escalation phase will be Open Label. The dose expansion phase will be masked to the subject, assessor and sponsor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Thickness Growth Rates</measure>
    <time_frame>52 weeks</time_frame>
    <description>Tumor Thickness growth rates over 52 weeks</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Ocular Melanoma</condition>
  <condition>Choroidal Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1 AU-011 &amp; Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 20 µg of AU-011 + 1 laser application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 AU-011 &amp; Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 40 µg of AU-011 + 1 laser application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 AU-011 &amp; Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 40 µg of AU-011 + 2 laser applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 AU-011 &amp; Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 2 treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 AU-011 &amp; Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest tolerated dose of AU-011/laser applications from Cohorts 1 to 3 administered weekly for 3 treatments. Up to 2 cycles of this regimen may be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 AU-011 &amp; Laser or Sham Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be randomized in a 1:1 ratio to receive either AU-011 (maximum tolerated dose regimen from Cohorts 1-5) or sham treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AU-011</intervention_name>
    <description>AU-011 Via Suprachoroidal Administration With a Dose Escalation with laser treatment</description>
    <arm_group_label>Cohort 1 AU-011 &amp; Laser</arm_group_label>
    <arm_group_label>Cohort 2 AU-011 &amp; Laser</arm_group_label>
    <arm_group_label>Cohort 3 AU-011 &amp; Laser</arm_group_label>
    <arm_group_label>Cohort 4 AU-011 &amp; Laser</arm_group_label>
    <arm_group_label>Cohort 5 AU-011 &amp; Laser</arm_group_label>
    <arm_group_label>Cohort 6 AU-011 &amp; Laser or Sham Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>Sham treatment includes sham injection and sham laser</description>
    <arm_group_label>Cohort 6 AU-011 &amp; Laser or Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)

          -  Have no evidence of metastatic disease confirmed by imaging

          -  Be treatment naïve for IL/CM

        Exclusion Criteria:

          -  Have known contraindications or sensitivities to the study drug or laser

          -  Active ocular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhijit Narvekar, MBBS</last_name>
    <role>Study Director</role>
    <affiliation>Aura Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rochelle M Summerfelt, MS</last_name>
    <phone>312-613-6006</phone>
    <email>rsummerfelt@aurabiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abhijit Narvekar, MBBS</last_name>
    <phone>617-319-8580</phone>
    <email>anarvekar@aurabiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Associates SW, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Chappell</last_name>
      <phone>520-733-8584</phone>
      <email>research@retinatucson.com</email>
    </contact>
    <investigator>
      <last_name>Cameron Javid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alisa Molina</last_name>
      <phone>310-794-5596</phone>
      <email>akmolina@med.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Tara McCannel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mariana Nunez</last_name>
      <phone>650-723-6995</phone>
      <email>mnunez1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Prithvi Mruthyunjaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCHealth Eye Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mary Preston</last_name>
      <email>MARY.PRESTON@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Scott Oliver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jayne Brown</last_name>
      <email>jmbrown@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Grossniklaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois At Chicago Illinois Eye and Ear Infirmary</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bhavana Kolli</last_name>
      <email>bkolli2@uic.edu</email>
    </contact>
    <investigator>
      <last_name>William Mieler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Gutierrez</last_name>
      <phone>617-391-5959</phone>
      <email>MariaElena_Gutierrez@meei.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Grayson Hanlon</last_name>
      <phone>617-573-5627</phone>
      <email>Grayson_Hanlon@meei.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ivana Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>W. K. Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pamela Campbell</last_name>
      <phone>734-936-0138</phone>
      <email>pamtitus@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Hakan Demirci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants, PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kendra Mellert</last_name>
      <phone>248-288-9132</phone>
      <phone_ext>1315</phone_ext>
      <email>kmellert@arcpc.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Capone Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Zoe Singer</last_name>
      <phone>212-305-3236</phone>
      <email>zs2423@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Marr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel Rusnak</last_name>
      <email>RusnakR@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Arun Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ann Lundquist</last_name>
      <email>lundquia@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Skalet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel Schwendeman</last_name>
      <phone>215-928-3105</phone>
      <email>rachel@shields.md</email>
    </contact>
    <contact_backup>
      <last_name>BaoNgoc Nguyen</last_name>
      <phone>(215) 928-7161</phone>
      <email>bnguyen@shields.md</email>
    </contact_backup>
    <investigator>
      <last_name>Carol Shields, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Carolina, PA</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauren Frazier</last_name>
      <phone>864-233-5722</phone>
      <phone_ext>1107</phone_ext>
      <email>lfrazier@retina-consultants.com</email>
    </contact>
    <investigator>
      <last_name>Chris Bergstrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas Health / Tennessee Retina, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Walden</last_name>
      <email>lwalden@tnretina.com</email>
    </contact>
    <investigator>
      <last_name>David Reichstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sally Arceneaux</last_name>
      <email>sarceneaux@texasretina.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Fuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chelsey Moore</last_name>
      <phone>713-394-7575</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Amy Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Dept of Ophthalmology &amp; Visual Sciences</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bonnie Verges</last_name>
      <phone>608-265-4659</phone>
      <email>verges@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Altaweel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aurabiosciences.com/</url>
    <description>Aura Biosciences</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveal Melanoma</keyword>
  <keyword>Eye Cancer</keyword>
  <keyword>Ocular Melanoma</keyword>
  <keyword>Choroidal Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

